The business model of Inmode Ltd revolves around providing innovative medical aesthetics solutions. Inmode Ltd develops and markets advanced, minimally-invasive technologies used in aesthetic and surgical procedures. Their cutting-edge platforms, such as BodyTite, FaceTite, and Morpheus8, offer solutions for skin tightening, body contouring, facial rejuvenation, and cellulite reduction. Inmode Ltd's business model centers on combining radiofrequency technology with other modalities to deliver safe, efficient, and customizable treatments for both medical professionals and patients. By continuously developing and enhancing their product portfolio, they aim to meet the growing demands of the global aesthetic market and cater to the evolving needs of healthcare practitioners.

Inmode Ltd is primarily active in the aesthetic medical device industry.

The main competitors of Inmode Ltd in the market include companies such as Cutera Inc., Cynosure Inc., Alma Lasers Ltd., and Lumenis Ltd. These companies offer similar products and services in the medical aesthetics industry, which Inmode operates in. With its innovative technologies and strong market presence, Inmode competes with these industry players to gain a larger market share and maintain its position as a leading provider of aesthetic solutions.

Inmode Ltd is a leading global provider of innovative energy-based medical aesthetic solutions. Established in 2008, the company has rapidly grown to become a trusted name in the industry. Inmode's cutting-edge technology focuses on radiofrequency-based devices, enabling physicians to deliver effective aesthetic treatments with precision and optimal patient satisfaction. Inmode Ltd is headquartered in Israel but operates worldwide, serving thousands of medical professionals and patients alike. With a commitment to continuously expanding its portfolio and investing in research and development, Inmode Ltd remains at the forefront of the medical aesthetics field, dedicated to enhancing the lives of individuals through advanced and safe technology.

Inmode Ltd, a leading provider of medical aesthetic systems, has achieved several significant milestones. The company has successfully pioneered advanced technology in minimally invasive and non-invasive procedures for aesthetic treatments. Inmode Ltd has gained worldwide recognition for its innovative platform, which includes advanced radiofrequency, laser, and pulsed light technologies. With a strong focus on research and development, they have introduced cutting-edge solutions that address a wide range of aesthetic concerns effectively and safely. Inmode Ltd continues to revolutionize the field of medical aesthetics, solidifying its position as a market leader and providing patients with exceptional treatment options.

Inmode Ltd is primarily present in various countries and regions worldwide. The company's presence extends to the United States, where it has a significant market presence. In addition, Inmode Ltd has established a strong presence in Europe, including key markets such as Germany, France, Italy, and the United Kingdom. The company also operates in the Asia-Pacific region, with a focus on countries like China and Japan. With its global reach, Inmode Ltd continues to expand its presence and deliver innovative solutions in the field of aesthetic medical technology.

Inmode Ltd represents a strong set of core values and a corporate philosophy that distinguishes the company. With a focus on innovation and cutting-edge technology, Inmode aims to provide transformative solutions in the aesthetic and medical markets. The company prides itself on quality, reliability, and versatility, ensuring that customers can trust their products and services. Inmode's commitment to research and development enables them to deliver advanced solutions, empowering healthcare professionals to enhance patient care and achieve optimal results. By prioritizing customer satisfaction and continuous improvement, Inmode Ltd strives to remain a leader in the industry.

Analysts currently set an average price target of 17,14 USD for the Inmode stock (median: 16,32 USD), implying +13,5 % versus the latest price. The consensus is based on 14 analyst ratings.

Inmode Cílové ceny analytiků 2026

14 analysts currently rate the Inmode stock: 7 recommend buying, 7 holding and 0 selling. For 2026, analysts expect Inmode to generate revenue of 370,32 Mil. USD and earnings per share of 1,32 USD.

Inmode Cílové ceny analytiků 2026

Converted at the current exchange rate, the Inmode share trades at 13,13 EUR (15,12 USD).

The Inmode share (INMD) is listed on 4 stock exchanges, including: NASDAQ (INMD), Frankfurt (154.F), München (154.MU), Düsseldorf (154.DU).

Inmode Ltd is a leading company in the medical technology industry, specializing in the development and commercialization of innovative aesthetic solutions. The company offers a wide range of products and services aimed at providing patients with fast, safe, and effective treatment for aesthetic problems. Inmode specializes in four main areas: body contouring and fat reduction, skin tightening, wrinkle reduction and skin rejuvenation, and common skin problems. To address these areas, the company has developed various advanced technologies and devices available to doctors and clinics. These include: - BodyTite: A revolutionary technology that uses radiofrequency energy to melt tissue, leading to effective body contouring with minimal invasiveness. - FaceTite: A technology based on the same principles as BodyTite but specifically developed for the face and neck to tighten loose skin and reduce wrinkles. - Morpheus8: A combination of micro-needles and radiofrequency energy that stimulates collagen production and tightens the skin, reducing wrinkles and unevenness. - Votiva: A device specifically designed for women that tightens the vagina and improves sexual health. These areas and products aim to cover the entire spectrum of aesthetic needs in order to build a successful and growing customer base. Inmode also has a unique business model that goes beyond traditional sales efforts. The company has developed a strong online presence that provides potential customers with everything they need to know about the company's products and services. Inmode has also built close relationships with medical professionals around the world to ensure that their products and technologies meet the highest medical standards. In addition to providing advanced medical devices to doctors and clinics, Inmode has also developed comprehensive training and support programs to ensure that doctors and clinics are trained in the use of their technologies and can achieve the best possible results for their patients. This business model has contributed to the company's growth and success in recent years, becoming a key factor in the aesthetic medicine industry. Overall, Inmode's business model demonstrates how innovative technologies and high-quality products and services, combined with online marketing and customer relationships, can lead to a successful company.

Tržby očekávané za Inmode činí 370,32 Mil. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.

Zisk očekávané za Inmode činí 84,69 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.

Poměr ceny k zisku (P/E) Inmode je aktuálně 11,44. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Inmode.

Poměr ceny k tržbám (P/S) Inmode je aktuálně 2,62. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Inmode.

Score kvality pro Inmode je 3/10.

ISIN Inmode je IL0011595993. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.

WKN Inmode je A2PP3A. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.

Ticker Inmode je INMD. Symbol tickeru se používá k obchodování akcií Inmode na burze.

Inmode vyplácela dividendu každý rok během posledních 0 let.

Inmode je přiřazena sektoru 'Zdravotnictví'.

Dividendy Inmode jsou vypláceny v USD.